Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
Harris Carla A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carla A. Harris received an award of 721 shares of common stock as part of non-management director compensation. The shares were valued at $71.17 each and are being deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, Harris directly holds 10,485 shares of MetLife common stock.
Seitz Michelle reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Michelle Seitz received a grant of 721 shares of Common Stock as part of her board compensation. The shares were awarded at a stated price of $0.00 per share as a non-management director retainer paid in MetLife common stock. Following this award, she holds 994 shares directly.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 721 shares of MetLife common stock on April 1, 2026, as part of non‑management director compensation. The shares were valued at $71.17 each and he elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Kennard is reported as beneficially owning 46,501 shares of MetLife common stock directly, and an additional 10 shares are held indirectly in the MetLife Policyholder Trust that holds stock allocated to eligible policyholders.
HUBBARD ROBERT GLENN reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Robert Glenn Hubbard received a grant of 1,248 shares of common stock valued at $71.17 per share as part of non-management director compensation. This award reflects retainer fees that are paid in MetLife stock rather than cash.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the shares are credited rather than immediately delivered. Following this grant, he holds 105,878 shares of MetLife common stock directly.
MORRISON DENISE M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Denise M. Morrison received a grant of 721 shares of MetLife common stock on 2026-04-01 as part of non-management director compensation arrangements. The shares were awarded at $0.00 per share, reflecting stock-based fees rather than a market purchase.
After this award, Morrison directly holds 34,711 shares of MetLife common stock. A portion of MetLife’s non-management director retainer fees is paid in common stock, so this transaction represents routine equity compensation rather than an open-market trade.
Mumenthaler Christian Stephane reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Christian Stephane Mumenthaler received an equity grant of MetLife common stock as part of his board compensation. On this Form 4, he was awarded 721 shares of common stock at $71.17 per share, increasing his directly reported holdings to 2,846 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock and that he elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the compensation is taken in stock units rather than immediate cash.
Hay Laura J reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Laura J. Hay received a grant of 721 shares of common stock valued at $71.17 per share as part of non-management director compensation. After this award on April 1, 2026, she directly holds 5,692 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock, and Hay elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This is a routine, compensation-related share award rather than an open-market purchase.
MCKENZIE DIANA reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Diana McKenzie received a grant of 721 shares of common stock, valued at $71.17 per share, as part of non-management director retainer fees. Following this award, she directly holds 24,472 shares. She elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Glaser Daniel S reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Daniel S. Glaser received an equity award of 721 shares of common stock, valued at $71.17 per share. The award represents a portion of his non-management director retainer fees paid in stock. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this grant, Glaser directly holds 2,101 shares of MetLife common stock. In addition, 198 shares are held indirectly in a GRAT, reflecting an estate-planning vehicle associated with his holdings.
GUTIERREZ CARLOS M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carlos M. Gutierrez received a grant of 721 shares of MetLife common stock on April 1, 2026. The shares were awarded at no cash cost as part of non-management director retainer fees paid in stock. Following this award, he directly holds 25,745 common shares and indirectly holds 18,807 additional shares through the Carlos M. Gutierrez Trust.